GlassScriptPhysician profile
Wilson C Kwan
NPI 1972958775
$20,381.31
in general payments reported to CMS, 2019-2025
28 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $162 · 2021: $52.61 · 2022: $1,103 · 2023: $3,139 · 2024: $2,649 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,068 · Consulting Fee: $4,023 · Travel and Lodging: $2,545 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,530 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,067.89 |
| Consulting Fee | $4,023.00 |
| Travel and Lodging | $2,545.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,530.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $8,913.41 | 2023-2025 | |
| Cvrx, INC. | $1,494.17 | 2023-2025 | Barostim Neo System |
| Abbott Laboratories | $1,411.62 | 2022-2025 | Triclip, Mitraclip |
| Pfizer INC. | $1,088.67 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $924.46 | 2023-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $917.69 | 2022-2025 | Lifevest |
| Amgen INC. | $909.49 | 2023-2025 | Repatha, Repatha, Otezla |
| Boston Scientific Corporation | $822.71 | 2019-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $628.00 | 2023-2025 | Farxiga, Brilinta, Wainua |
| E.R. Squibb & Sons, L.L.C. | $547.67 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $512.15 | 2019-2025 | Verquvo, Belsomra |
| Novartis Pharmaceuticals Corporation | $439.80 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $241.75 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $238.80 | 2023-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $218.27 | 2025 | Assure Wcd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $204.88 | 2024-2025 | Wegovy, Ozempic |
| Lantheus Medical Imaging, INC. | $159.24 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $150.69 | 2022-2025 | Evkeeza |
| Penumbra, INC. | $145.73 | 2022 | |
| Alnylam Pharmaceuticals INC. | $106.22 | 2023-2024 | Amvuttra |
| Scpharmaceuticals INC. | $80.11 | 2025 | |
| Esperion Therapeutics, INC. | $59.08 | 2024-2025 | Nexletol |
| Philips North America LLC | $48.53 | 2023-2024 | (Cm9) Amb Mon & Diag Und |
| Resmed Corp | $45.99 | 2025 | |
| Irhythm Technologies, INC. | $22.51 | 2023 | Zio Xt Patch |
| Lilly USA, LLC | $18.78 | 2025 | Zepbound, Mounjaro |
| Bsn Medical INC | $15.98 | 2025 | |
| Glaxosmithkline, LLC. | $14.91 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilson Kwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.